HCPCS J7674: Methacholine Inhalation Solution for Nebulizer, per 1 mg

HCPCS Level II code J7674 denotes methacholine chloride supplied as an inhalation solution for nebulizer administration, billed per 1 mg. Methacholine is a bronchoprovocation agent used in pulmonary function testing to evaluate airway hyperresponsiveness and support diagnoses such as asthma. Accurate coding of J7674 is important for standardized reporting of diagnostic respiratory procedures and for clear communication between clinicians, facilities, and payers nationwide.

Key payers in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for use of methacholine in bronchoprovocation testing, typical sites of service where the medication is administered, and what to expect in claims processing in general terms. The publication provides benchmarks and payer coverage context where available, notes on common billing modifiers, and links between the medication supply code and the diagnostic service line.

This resource aims to help billing professionals, clinicians, and compliance staff understand the role of HCPCS Level II code J7674 in the diagnostic workflow, common billing considerations, and the broader clinical relevance of methacholine-based bronchoprovocation testing across outpatient and hospital settings.

Billing Code Overview

HCPCS Level II code J7674 describes methacholine chloride administered as an inhalation solution through a nebulizer, per 1 mg. This service represents the provision of a nebulized bronchoprovocation agent used to assess airway hyperresponsiveness during pulmonary function testing.

Service type: Diagnostic bronchoprovocation agent administration
Typical site of service: Pulmonary function laboratory, outpatient clinic, or hospital outpatient department where nebulized methacholine is administered under medical supervision

Clinical Context

A 28-year-old patient with episodic exertional wheeze and normal baseline spirometry is referred to a pulmonary function laboratory for a bronchoprovocation test using methacholine. The procedure is ordered to evaluate airway hyperresponsiveness when history and physical exam suggest asthma but baseline spirometry is non-diagnostic. The patient arrives at an outpatient pulmonary clinic or hospital-based pulmonary function lab. Vital signs and baseline spirometry are obtained; contraindications (recent myocardial infarction, uncontrolled hypertension, pregnancy, severe airflow obstruction) are screened. A trained pulmonary function technologist prepares methacholine chloride solution and a nebulizer. Incremental concentrations of methacholine are administered via nebulizer, typically in doubling concentrations, and spirometry (FEV1) is measured after each dose. The test is discontinued when either the patient experiences a 20% or greater fall in FEV1 from baseline, unacceptable symptoms occur, or the maximal protocol dose is reached. Short-acting bronchodilator (e.g., albuterol) and emergency equipment are immediately available. The result is documented in the pulmonary function report and used by the ordering clinician to confirm or exclude bronchial hyperreactivity and guide management decisions.

Coding Specifications

Modifier	Description	When to Use
`26`	Professional component	When billing professional interpretation by a physician separate from technical administration of the methacholine inhalation.

Taxonomy Code	Specialty	Notes
`207RH0000X`	Pulmonary Disease	Specialists who commonly order and interpret bronchoprovocation testing.
`2084P0800X`	Allergy & Immunology	Allergy specialists who evaluate airway hyperresponsiveness as part of asthma assessment.
`363A00000X`	Diagnostic Pulmonary Function Technologist	Technologists who administer nebulized methacholine and perform spirometry.
`207L00000X`	Internal Medicine	Primary care or hospital-based internists who may refer and interpret results.
`207Q00000X`	Family Medicine	Family physicians who refer patients for testing and use results in outpatient management.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`J45.90`	Asthma, unspecified, uncomplicated	Common indication for methacholine challenge when asthma is suspected but not confirmed by baseline testing.
`R06.2`	Wheezing	Symptom prompting evaluation with bronchoprovocation testing to assess reversible airway obstruction.
`R05`	Cough	Chronic cough of uncertain etiology may be evaluated with methacholine challenge to assess for cough-variant asthma.
`Z13.6`	Encounter for screening for respiratory disorders	Sometimes used when screening for airway hyperresponsiveness in occupational or pre-employment evaluations.
`J98.01`	Acute bronchospasm	Used when characterizing current bronchospastic symptoms; testing helps quantify airway reactivity.
`J44.9`	Chronic obstructive pulmonary disease, unspecified	In select diagnostic workups where mixed obstructive disease and hyperreactivity are considered; use cautiously due to contraindications.
`R06.89`	Other abnormalities of breathing	Non-specific breathing abnormalities that may prompt bronchoprovocation testing to evaluate airway responsiveness.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`94010`	Bronchospasm, spirometry with bronchodilator response	Baseline and post-bronchodilator spirometry performed before/after challenge to document airway reversibility.
`94070`	Bronchospasm provocation study; methacholine challenge	Directly related procedure code for formal bronchoprovocation testing using methacholine; often reported alongside or as the primary test.
`94760`	Noninvasive ear or pulse oximetry for oxygen saturation; single determination	Used during the challenge to monitor oxygen saturation for patient safety.
`99152`	Moderate sedation services provided by the same physician performing the diagnostic or therapeutic service, initial 15 minutes	Rarely used; only if moderate sedation is required for patient tolerance during the procedure (use per payer rules).
`94060`	Bronchospasm provocation monitoring of drug administration and interpretation (home or office)	Used when documenting monitoring and interpretation related to bronchoprovocation protocols in certain settings.

OpenPayer

Summary & Overview